Logo

Vol. 121, No. 3

February 28, 2011
On this page
Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease
Małgorzata Saryusz‑Wolska, Elektra Szymańska‑Garbacz, Maciej Jabłkowski, Jolanta Białkowska, Maciej Pawłowski, Ewa Kwiecińska, Aleksandra Omulecka, Anna Borkowska, Anna Ignaczak, Jerzy Loba, Leszek Czupryniak
Pol Arch Intern Med. 2011, Vol. 121, No. 3: 61–66; DOI: 10.20452/pamw.1023
Assessment of skin autofluorescence as a marker of advanced glycation end product accumulation in type 1 diabetes
Paweł Samborski, Dariusz Naskręt, Aleksandra Araszkiewicz, Paweł Niedźwiecki, Dorota Zozulińska‑Ziółkiewicz, Bogna Wierusz‑Wysocka
Pol Arch Intern Med. 2011, Vol. 121, No. 3: 67–72; DOI: 10.20452/pamw.1025
Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management
James D. Douketis
Pol Arch Intern Med. 2011, Vol. 121, No. 3: 73–80; DOI: 10.20452/pamw.1027
Do we have enough data to confirm the link between antidiabetic drug use and cancer development?
Józef Drzewoski, Agata Drozdowska, Agnieszka Śliwińska
Pol Arch Intern Med. 2011, Vol. 121, No. 3: 81–87; DOI: 10.20452/pamw.1029
Can we prolong life of patients with advanced chronic kidney disease: what is the clinical evidence?
Tomasz Stompór, Artur Olszewski, Irena Kierzkowska
Pol Arch Intern Med. 2011, Vol. 121, No. 3: 88–93; DOI: 10.20452/pamw.1031